guest ::
| Home > Publications database > IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria > print |
| Home > Publications database > IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria > print |
| 001 | 1053904 | ||
| 005 | 20260201105311.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noaf201.1140 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 037 | _ | _ | |a FZJ-2026-01602 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Peplinski, Jana-Marie |0 P:(DE-HGF)0 |b 0 |
| 111 | 2 | _ | |a 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies |g SNO / WFNOS 2025 |c Honolulu |d 2025-11-20 - 2025-11-23 |w USA |
| 245 | _ | _ | |a IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1769939567_17710 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a AbstractBACKGROUNDWe evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their ability to predict longer overall survival (OS) in patients with glioblastoma treated with bevacizumab-based regimens at relapse.PATIENTS AND METHODSThirty-eight adult patients with IDH-wildtype glioblastoma were identified from three previously published studies. All patients (i) received bevacizumab in combination with a second agent (irinotecan, lomustine, or nivolumab), (ii) underwent MRI- and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging at baseline and at a median time of 8 weeks (range, 4-12 weeks) after treatment initiation, and (iii) had available PET-derived parameters, i.e., metabolic tumor volume (MTV), maximum and mean tumor-to-brain ratios (TBRmax and TBRmean). A post-hoc analysis was performed to evaluate the predictive value of the PET RANO 1.0 criteria. In addition, ROC analyses were performed to define PET parameter thresholds for predicting an OS≥9 months. Furthermore, response prediction using the RANO 2.0 criteria for MRI was compared with the PET RANO 1.0 criteria.RESULTSAccording to the PET RANO 1.0 criteria, patients fulfilling the criterion Stable Disease (n=10), Partial Response (n=19), or Complete Response (n=1) had a significantly longer OS than patients with Progressive Disease (n=8) (9.0 vs. 4.0 months; P=0.001). Among the suggested thresholds by the PET RANO 1.0 criteria, only a MTV reduction ≥40% was significantly predictive of response (7.3 vs. 4.0 months; P=0.008). Optimal thresholds identified by ROC analysis differed from those proposed by the PET RANO 1.0 criteria. A reduction in MTV by ≥30% and in TBRmean by ≥4% were both predictive of longer OS (7.3 vs. 4.0 months; P=0.008, and 10.6 vs. 6.0 months; P=0.010, respectively). The RANO 2.0 criteria were less significant to predict a longer OS (9.0 vs. 6.0 months; P=0.015).CONCLUSIONPET RANO 1.0 criteria appear to be effective in predicting response to bevacizumab-based therapy in glioblastomas at relapse. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Ceccon, Garry |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Wollring, Michael |0 P:(DE-Juel1)190394 |b 3 |
| 700 | 1 | _ | |a Stetter, Isabelle |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Rosen, Jurij |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Rosen, Elena |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Kraft, Manuel |0 P:(DE-Juel1)208037 |b 7 |u fzj |
| 700 | 1 | _ | |a Fink, Gereon |0 P:(DE-Juel1)131720 |b 8 |u fzj |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 9 |u fzj |
| 700 | 1 | _ | |a Lohmann, Philipp |0 P:(DE-Juel1)145110 |b 10 |u fzj |
| 700 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 11 |u fzj |
| 773 | _ | _ | |a 10.1093/neuonc/noaf201.1140 |0 PERI:(DE-600)2094060-9 |y 2025 |g Vol. 27, no. Supplement_5, p. v287 - v287 |x 1523-5866 |
| 856 | 4 | _ | |u https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v287/8319142 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)208037 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)131777 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)145110 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)143792 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2024-12-11 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-11 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2024-12-11 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 0 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|